Quarterly ResultMay 4, 2026, 08:32 AM
NewGen Reports FY2025 Net Profit $9.9M, Total Assets $32.7M
AI Summary
NewGenIVF Group reported strong fiscal year 2025 results, including a net profit attributable to shareholders of US$9.9 million and total assets of US$32.7 million as of December 31, 2025. The significant profit was primarily due to a US$19.2 million bargain purchase gain from the acquisition of advanced cytometry intellectual property in July 2025. The company also authorized a US$2 million share repurchase program in November 2025 and continued progress on diversification initiatives in digital assets and health supplements.
Key Highlights
- Net profit attributable to shareholders for fiscal year 2025 was US$9.9 million.
- Total assets as of December 31, 2025, were US$32.7 million, up from US$3.6 million in 2024.
- Total assets per share were US$135.9 as of December 31, 2025.
- Acquisition of advanced cytometry intellectual property in July 2025 generated a US$19.2 million bargain purchase gain.
- The acquired intellectual property was independently valued at US$17.9 million.
- Authorized a US$2 million share repurchase program in November 2025.
- Continued progress on diversification initiatives through NewGenDigital and NewGenSup.